ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mavorixafor

Also written as “Mavorixafor”, “X4P-001” and “AMD11070”.

Its studies are mostly in Neutropenia · Carcinoma, Renal Cell · Hepatic Insufficiency · Waldenstrom Macroglobulinemia · Triple Negative Breast Neoplasms, led by 3 companies.

Drug pageMavorixafor: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 19, 201914 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
X4 Pharmaceuticals122 open or runningphase 3since Jun 19, 2019Jan 20, 2016Sep 2027phase 3 · NCT06056297
Abbisko Caymanits history only10 open or runningphase 2since Sep 25, 2021Sep 25, 2021none ahead
Sanofiits history only10 open or runningphase 1since Aug 3, 2006Aug 3, 2006none ahead

Also a collaborator on its studies: Covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of X4 Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2016First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT02667886 · 74 enrolled · United States, Korea, Republic of
  2. Feb 4, 2016Phase 1 study in HealthyNCT02680782 · 15 enrolled · United States
  3. Jul 1, 2016Phase 1 study in MelanomaNCT02823405 · 16 enrolled · United States
  4. Sep 30, 2016Phase 2 study in Carcinoma, Renal CellNCT02923531 · 9 enrolled · United States
  5. Dec 20, 2016Phase 2 study in WHIM syndromeNCT03005327 · 8 enrolled · United States, Australia
  6. Dec 9, 2017Named mavorixaforINNProposed as its International Nonproprietary Name in WHO's List 118 · before, X4P-001, AMD11070
  7. Jun 19, 2019Phase 3 study in WHIM syndromeNCT03995108 · 31 enrolled · United States, Australia, Austria and more
  8. Nov 4, 2019Phase 2 study in NeutropeniaNCT04154488 · 32 enrolled · United States
  9. Feb 12, 2020Phase 1 study in Waldenstrom MacroglobulinemiaNCT04274738 · 16 enrolled · United States, Greece
  10. Sep 20, 2023Phase 3 study in NeutropeniaNCT06056297 · 176 planned · United States, Argentina, Australia and more
  11. Feb 27, 20252 phase 1 studiesNCT06914869, NCT06858696
  12. Oct 20, 2026Phase 2 study in Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersNCT07902830 · 40 planned

Ahead

  1. Sep 2027Primary completion: phase 3 study in NeutropeniaNCT06056297
  2. Jan 30, 2029Primary completion: phase 2 study in Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersNCT07902830

TargetBeta

CXCR4 →read by rule
“An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), ”NCIt, by rule
“C-X-C chemokine receptor type 4 antagonist”ChEMBL 37, by rule

Studies

All 12 X4 Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07902830Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders2Not yet recruitingJan 30, 202940
NCT06914869Healthy Participants · United States1CompletedMay 19, 202538
NCT06858696Hepatic Insufficiency · United States1CompletedJan 12, 202639
NCT06056297Neutropenia · United States, Argentina, Australia and more3RecruitingSep 2027176
NCT04274738Waldenstrom Macroglobulinemia · United States, Greece1CompletedOct 31, 202216
NCT04154488Neutropenia · United States2CompletedAug 27, 202432
NCT03995108WHIM syndrome · United States, Australia, Austria and more3CompletedDec 23, 202531
NCT03005327WHIM syndrome · United States, Australia2CompletedJun 16, 20228
NCT02923531Carcinoma, Renal Cell · United States2TerminatedAug 8, 20189
NCT02823405Melanoma · United States1CompletedMar 15, 201816
NCT02680782Healthy · United States1TerminatedFeb 28, 201615
NCT02667886Carcinoma, Renal Cell · United States, Korea, Republic of2CompletedApr 14, 202274

How it is read

Names in the registry

  • “Mavorixafor”, 7 entries
  • “X4P-001”, 6 entries
  • “AMD11070”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.